Engineering electrically conducting tissue for the heart

Jun 19, 2006
A tissue-engineered pacemaker substitute?
Engineered tissue provides an electrical connection between the atria (not shown) and the ventricles (at left). Cardiac cells appear in red and green, and the implanted cells in green alone. Credit: Courtesy Douglas Cowan, PhD, Children's Hospital Boston

Patients with complete heart block, or disrupted electrical conduction in their hearts, are at risk for life-threatening rhythm disturbances and heart failure. The condition is currently treated by implanting a pacemaker in the patient's chest or abdomen, but these devices often fail over time, particularly in infants and small children who must undergo many re-operations. Researchers at Children's Hospital Boston have now taken preliminary steps toward using a patient's own cells instead of a pacemaker, marking the first time tissue-engineering methods have been used to create electrically conductive tissue for the heart.

Results appear in the July issue of the American Journal of Pathology (published online on June 19).

In complete heart block, electrical signals cannot pass from the heart's upper chambers (atria) to the lower chambers (ventricles), leading to heart failure. In normal hearts, electrical impulses move first through the atria, then pause at the atrioventricular (AV) node. Then, after a short delay that allows the ventricles to fill with blood, the AV node releases the impulses, which move through the ventricles causing them to contract. In this way, the beats of the atria and ventricles are synchronized.

Electrically conducting implants for the heart
Collagen and myoblasts (precursor cells derived from skeletal muscle) were cast into molds made up of pieces of tubing and polyester mesh (seen at each end). Once it gels, the tissue is strong enough to hold a surgical suture. The myoblasts align longitudinally between the mesh, allowing surgeons to implant them in a particular orientation within the heart. Credit: Courtesy Douglas Cowan, PhD, Children's Hospital Boston

Investigators led by Douglas Cowan, PhD, a cell biologist in Children's Department of Anesthesiology, Perioperative and Pain Medicine, wanted to create a biological substitute for the AV node that would work in patients who have defective atrioventricular conduction. "The idea was that rather than using a pacemaker, we could create an electrical conduit to connect the atria and ventricles," Cowan says.

Cowan's team, including first author Yeong-Hoon Choi in Children's Department of Cardiac Surgery, obtained skeletal muscle from rats and isolated muscle precursor cells called myoblasts. They "seeded" the myoblasts onto a flexible scaffolding material made of collagen, creating a 3-dimensional bit of living tissue that could be surgically implanted in the heart.

The cells distributed themselves evenly in the tissue and oriented themselves in the same direction. Tested in the laboratory, the engineered tissue started beating when stimulated electrically, and its muscle cells produced proteins called connexins that channel ions from cell to cell, connecting the cells electrically.

When the engineered tissue was implanted into rats, between the right atrium and right ventricle, the implanted cells integrated with the surrounding heart tissue and electrically coupled to neighboring heart cells. Optical mapping of the heart showed that in nearly a third of the hearts, the engineered tissue had established an electrical conduction pathway, which disappeared when the implants were destroyed. The implants remained functional through the animals' lifespan (about 3 years).

"The advantage of using myoblasts is that they can be taken from skeletal muscle rather than the heart itself--which will be important for newborns whose hearts are so tiny they cannot spare any tissue for the biopsy--and that they're resistant to ischemia, meaning they can go without a good blood supply for a relatively long period of time," Cowan says.

Cowan and his team are now working with a large-animal model that more closely simulates pediatric heart block. Further studies will seek to create tissue-engineered grafts that behave more like a natural AV node, for example by providing a built-in delay before sending electrical signals to the ventricles. The team is investigating whether other cell types, such as stem cells derived from muscle or bone marrow, might be made to behave more like AV node cells.

Complete heart block is present in about 1 in 22,000 births. It can also result from congenital heart disease, through an injury or scar tissue from heart surgery, or as a side effect of medications. In adults, pacemakers are a good solution, but in children, they carry a greater risk of heart perforation and clot formation. In addition, pacemakers only last 3 to 5 years in children, and the leads must be replaced frequently, requiring many repeat operations. In very small babies, the pacemaker leads must be positioned on the heart surface, resulting in even greater failure rates.

Cowan envisions a future in which a child with heart block would receive a conventional pacemaker, but also receive an implant of engineered, electrically conducting tissue that would grow along with the child. The pacemaker, acting as a backup, would start functioning only if the biological implant failed, prolonging its useful life.

Source: Children's Hospital Boston

Explore further: US experts skeptical of testosterone drug benefits

add to favorites email to friend print save as pdf

Related Stories

Team makes scientific history with new cellular connection

Sep 11, 2014

Researchers led by Dr. Helen McNeill at the Lunenfeld-Tanenbaum Research Institute have revealed an exciting and unusual biochemical connection. Their discovery has implications for diseases linked to mitochondria, ...

Straight to the heart

Aug 18, 2014

A battery-less, wirelessly-powered implantable defibrillator for atrial fibrillation is being developed by an international team of researchers in the UK, Venezuela and the US. With the ability to sense the ...

Venom gets good buzz as potential cancer-fighter

Aug 11, 2014

Bee, snake or scorpion venom could form the basis of a new generation of cancer-fighting drugs, scientists will report here today. They have devised a method for targeting venom proteins specifically to malignant cells while ...

Recommended for you

US experts skeptical of testosterone drug benefits

39 minutes ago

U.S. health experts say there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging and large studies are needed to support their continued use in millions of American men.

France to receive first Ebola patient

42 minutes ago

France on Wednesday prepared to receive its first Ebola patient, as the World Bank warned the spiralling epidemic is threatening economic catastrophe in west Africa.

Study: Americans endure unwanted care near death

58 minutes ago

Americans suffer needless discomfort and undergo unwanted and costly care as they die, in part because of a medical system ruled by "perverse incentives" for aggressive care and not enough conversation about what people want, ...

User comments : 0